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Background: Human African trpanosomiasis (HAT) is
caused by the protozoan parasites Trypanosoma brucie gam-
biense (T.b.g) and Trypanosoma brucie rhodesiense (T.b.r)
and is usually fatal when left untreated. It is one of the
most neglected tropical diseases in the world causing an
estimated 50,000 deaths annually. Current drug therapy suf-
fers from high toxicity, undesirable intravenous route of
administration and emergence of parasite resistance. The
present study is to evaluate the trypanocidal activity of a
novel series of alkanediamide-linked bisbenzamidines and
bisbenzamidoximes against several clinical isolates of Try-
panosoma brucie.
Methods: A series of 20 bisbenzamidines and bisbenza-
midoximes were synthesized and tested in vitro against a
drug-sensitive strain of T. b. brucei Lab 110 EATRO and a
drugresistant strain of T. b. r. KETRI 243. The bisamidoximes
were designed to improve oral bioavailability by functioning
as orally-active prodrugs of the most active bisamidines. The
in vivo efﬁcacy of 8 bisbenzamidines and bisbenzamidoximes
were evaluated using mice infected with the drug-sensitive
(T. b. brucei Lab 110 EATRO) or drug-resistant strains of
T.b.r. KETRI 2002 and KETRI 2538.
Results: The tested compounds generally showed sim-
ilar in vitro potencies against both strains of T.b. The
most potent compounds were bisbenzamidines linked with
a hexanediamide, heptanediamide or octanediamide group
(inhibitory concentration for 50% (IC50) = 1-3 nM). Several
of the most potent bisbenzamidine compounds were effec-
tive in curing mice infected with the drug-sensitive or
drug-resistant strains of T. b. rhodesiense. Curative doses
were < 15mg/kg/day for 3 days given by the intraperi-
toneal injection in the mouse model of infections. However,
replacing the terminal basic bisamidines with less basic
bisamidoxime groups resulted in prodrugs that were not
orally effective against T. b. brucei infected mice.
Conclusion: The results suggest that alkanediamide-
linked bisbenzamidines are highly effective against T.
brucei, but further optimization of the prodrug strategy is
needed to improve their oral bioavailability.
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T
2
b
3
T
d
t
W
o
I
bts e439
2.006
critical role of CD2 as an immunoprophylactic agent to
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Background: A major Concern for VL prevention appears
o be the inability of their CD4+ T cells to mount an ade-
uate TH1 response which ensures the possible cure of the
isease. Similarly the effectiveness of SAG in intact animal
s determined by the host cell-mediated immune response.
he present study aims at evaluating the use of CD2 antibody
s an immunotherapeutic agent along with SAG in ensur-
ng treatment of BALB/c mice induced with experimental
isceral leishmaniasis.
Methods: Mice were infected with Leishmania donovani
romastigotes. Another set served as control. After seven
eek of infection, a set of mice from infected group was sub-
ected to SAG treatment and another group was subjected
o SAG treatment along with stimulation with antiCD2 anti-
ody.CD4 cells expressing CD-25 were immunophenotyped
nd cytokines like IL-2, IFN- and TNF- were assessed using
ACS. We also looked into cell cycle pattern, expression of
D25+ cells on T cells, percentage of lymphocytes converted
nto lymphoblasts, percentage of activated T lymphocytes
nd IL-2 production. These parameters were evaluated in T
ells both before and after stimulation of their CD2 antigen.
Results: We recorded a substantial enhancement of pro-
ective cytokines which are essential for combating visceral
eishmaniasis infection.We also observed a signiﬁcant reduc-
ion in parasitic load when drugs are used in combination
ith this immunoprophylactic agent
Conclusion: CD2 proved to be an important immunopro-
hylactic agent which if used in combination with drugs can
rovide a suitable and substantial cure against visceral leish-
aniasis
oi:10.1016/j.ijid.2010.02.595
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Background: Visceral Leishmaniasis (VL) is a parasitic
isease caused by Leishmania infantum. It is transmitted
hrough bites of infected sand ﬂies (female Phlebotomus).
e aimed to investigate bone marrow and blood samples
btained from the patients with suspected VL.
Methods: Fifty-nine patients with suspected VL from
stanbul were included in this work. Bone marrow and
lood samples of these patients were tested for possible VL
